DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04979611

UnknownPhase 1

The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

60

estimated

Study population

Oncology

Key I/E criterion

—

Primary endpoint

•Standard uptake value (SUV)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04979611
Org study IDFirstAHFujian11

Timeline

Milestones

Study start2020-08-01actual
Study first posted2021-07-28actual
Last update posted2023-09-21actual
Primary completion2025-08-01estimated
Study completion2025-08-01estimated

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Oncology

Eligibility

Who can enroll

Minimum age6 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•1.age ≥6 years old 2.Patients with hypoglycaemia 3.Endogenous hyperinsulinemic hypoglycaemia 4.Enhanced CT or MRI within 1 month 5.Signed written consent

Exclusion criteria

•1. Breast feeding 2.Pregnancy or the wish to become pregnant within 6 months 3.Renal function: serum creatinine during 41-73umol/L 4.Any medical condition may significantly interfere with study compliance; 5.Known allergy

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Standard uptake value (SUV)

Time frame:From right after tracer injection to 1-hours post-injection

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.